Management of warfarin (coumarin) overdose

被引:48
作者
Baglin, T [1 ]
机构
[1] Addenbrookes NHS Trust, Dept Haematol, Cambridge CB2 2QQ, England
关键词
D O I
10.1016/S0268-960X(98)90020-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment with coumarin oral anticoagulants, such as warfarin, is effective antithrombotic therapy, but patients treated with these drugs are at significant risk of bleeding. The risk of haemorrhage increases with increasing intensity of anticoagulation and overanticoagulation is common. Reversal can be achieved by stopping the coumarin drug or administration of vitamin K, fresh frozen plasma or coagulation factor concentrates. However, there are surprisingly few studies defining the optimum dose of these products and there are no randomized studies comparing the relative benefit and risk of coagulation factor concentrates versus fresh frozen plasma. Guidelines for the management of overdose are based on level III and IV evidence and are, therefore, only grade B recommendations at best. Further studies are required to determine the most effective use of products and the dose required for safe reversal of overanticoagulation.
引用
收藏
页码:91 / 98
页数:8
相关论文
共 53 条
[31]   Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT) [J].
Palareti, G ;
Leali, N ;
Coccheri, S ;
Poggi, M ;
Manotti, C ;
DAngelo, A ;
Pengo, V ;
Erba, N ;
Moia, M ;
Ciavarella, N ;
Devote, G ;
Berrettini, M ;
Musolesi, S .
LANCET, 1996, 348 (9025) :423-428
[32]  
PALARETTI G, 1996, ORAL ANTICOAGULANTS, P264
[33]   REVERSAL OF EXCESSIVE EFFECT OF REGULAR ANTICOAGULATION - LOW ORAL DOSE OF PHYTONADIONE (VITAMIN-K1) COMPARED WITH WARFARIN DISCONTINUATION [J].
PENGO, V ;
BANZATO, A ;
GARELLI, E ;
ZASSO, A ;
BIASIOLO, A .
BLOOD COAGULATION & FIBRINOLYSIS, 1993, 4 (05) :739-741
[34]  
Philippou H, 1996, THROMB HAEMOSTASIS, V76, P23
[35]  
POLLER L, 1964, LANCET, V2, P62
[36]  
POLLER L, 1996, ORAL ANTICOAGULANTS, P49
[37]  
POLLER L, 1996, ORAL ANTICOAGULANTS, P280
[38]   HYDROXYLATION OF WARFARIN BY HUMAN CDNA-EXPRESSED CYTOCHROME-P-450 - A ROLE FOR P-4502C9 IN THE ETIOLOGY OF (S)-WARFARIN DRUG-INTERACTIONS [J].
RETTIE, AE ;
KORZEKWA, KR ;
KUNZE, KL ;
LAWRENCE, RF ;
EDDY, AC ;
AOYAMA, T ;
GELBOIN, HV ;
GONZALEZ, FJ ;
TRAGER, WF .
CHEMICAL RESEARCH IN TOXICOLOGY, 1992, 5 (01) :54-59
[39]   PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN AT STEADY-STATE [J].
ROUTLEDGE, PA ;
CHAPMAN, PH ;
DAVIES, DM ;
RAWLINS, MD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 8 (03) :243-247
[40]  
Sadowski JABS, 1996, ORAL ANTICOAGULANTS, P9